Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DU47SF
|
|||
| Drug Name |
Crizanlizumab
|
|||
| Synonyms |
SEG101
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Vaso-occlusive crisis [ICD-11: BE2Y; ICD-10: D57.00; ICD-9: 282.62] | Approved | [1] | |
| Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 4 | [2] | ||
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin (SELP) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Malaria | ||||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| amb2 Integrin signaling | ||||
| Reactome | Platelet degranulation | |||
| Cell surface interactions at the vascular wall | ||||
| WikiPathways | Human Complement System | |||
| Spinal Cord Injury | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | ClinicalTrials.gov (NCT04662931) An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients. U.S. National Institutes of Health. | |||
| REF 3 | Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.